Yuna Kim

Dr. Yuna Kim

Yonsei University College of Medicine
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2021 in Gut and Liver
Verified
Journal Article
Open access
PDF file
YKYuna Kim
Yuna Kim
EHEugene Han
Eugene Han
JLJae Seung Lee
Jae Seung Lee
HLHye Won Lee
Hye Won Lee
BKBeom Kyung Kim
Beom Kyung Kim
Seung Up KimSeung Up Kim
Seung Up Kim
Yuna Kim, Eugene Han, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Mi Kyung Kim, Hye Soon Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee, and Seung Up Kim. Gut and Liver 2022;16:290-9. https://doi.org/10.5009/gnl210084

1 January 2023 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
YKYuna Kim
Yuna Kim
Sung Hwan YooSung Hwan Yoo
Sung Hwan Yoo
JCJaeyoung Chun
Jaeyoung Chun
JKJie-Hyun Kim
Jie-Hyun Kim
YYYoung-Hoon Youn
Young-Hoon Youn
HPHyojin Park
Hyojin Park
Kim Y, et al. Yonsei Med J. 2023 Jan;64:e13. https://doi.org/10.3349/ymj.2022.0319

Verified
Journal Article
Open access
PDF file
YKYuna Kim
Yuna Kim
HYHyeok Jun Yun
Hyeok Jun Yun
KCKyung Hwa Choi
Kyung Hwa Choi
CKChan Wung Kim
Chan Wung Kim
JLJae Ha Lee
Jae Ha Lee
Ki-cheong ParkKi-cheong Park
Ki-cheong Park
Thyroid cancer is the most well-known type of endocrine cancer that is easily treatable and can be completely cured in most cases. Nonetheless, anti-cancer drug-resistant metastasis or recurrence may occur and lead to the failure of cancer therapy, which eventually leads to the death of a patient with cancer. This study aimed to detect novel thyroid cancer target candidates based on validating and identifying one of many anti-cancer drug-resistant targets in patient-derived sorafenib-resistant papillary thyroid cancer (PTC). We focused on targeting the sarco/endoplasmic reticulum calcium ATPase (SERCA) in patient-derived sorafenib-resistant PTC cells compared with patient-derived sorafenib-sensitive PTC cells. We discovered novel SERCA inhibitors (candidates 33 and 36) by virtual screening. These candidates are novel SERCA inhibitors that lead to remarkable tumor shrinkage in a xenograft tumor model of sorafenib-resistant patient-derived PTC cells. These results are clinically valuable for the progression of novel combinatorial strategies that facultatively and efficiently target extremely malignant cancer cells, such as anti-cancer drug-resistant PTC cells.

21 February 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
YKYuna Kim
Yuna Kim
JLJae Seung Lee
Jae Seung Lee
HLHye Won Lee
Hye Won Lee
BKBeom Kyung Kim
Beom Kyung Kim
JPJun Yong Park
Jun Yong Park
Seung Up KimSeung Up Kim
Seung Up Kim
Background: Trans-arterial radioembolization (TARE) has shown promising results in treating hepatocellular carcinoma (HCC). We identified independent predictors of radiological complete response (CR) in patients with intrahepatic HCC who were treated with TARE. Methods: Patients with intrahepatic HCC treated with TARE between 2011 and 2017 were recruited. CR was defined according to the modified Response Evaluation Criteria in Solid Tumors. Cox regression analysis was used to determine independent predictors of CR. Results: The median age of study participants (83 men and 19 women) was 64.3 years. The mean survival after TARE was 55.5 months, and 21 (20.6%) patients died during the study period. Patients who achieved CR (14 patients, 13.7%) had significantly higher serum albumin level (median 4.1 vs. 3.9 g/dL), lower total bilirubin level (median 0.6 vs. 0.7 mg/dL), lower aspartate aminotransferase level (median 30.0 vs. 43.0 IU/L), lower alkaline phosphatase level (median 79.0 vs. 103.0 IU/L), lower alpha-fetoprotein level (median 12.7 vs. 39.9 ng/mL), lower des-gamma-carboxyprothrombin level (median 575.5 vs. 2772.0 mAU/mL), lower model for end-stage liver disease (MELD) score (median 6.0 vs. 7.0), and smaller maximal tumor diameter (median 6.3 vs. 9.0 cm) compared to those who did not achieve CR (all p < 0.005). Multivariate Cox regression analysis showed that lower MELD score (hazard ratio (HR) = 0.436, p = 0.015) and maximal tumor size < 9 cm (HR = 11.180, p = 0.020) were independent predictors of an increased probability of radiological CR after TARE. Conclusions: Low MELD score and small maximal tumor size were independently associated with an increased probability of CR after TARE in patients with intrahepatic HCC.

3 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YKYuna Kim
Yuna Kim
HKHyunki Kim
Hyunki Kim
MJMin Kyu Jung
Min Kyu Jung
SRSun Young Rha
Sun Young Rha
HCHyun Cheol Chung
Hyun Cheol Chung
Sang Kil LeeSang Kil Lee
Sang Kil Lee
In cases of progression despite chemotherapy, collecting gastric cancer (GC) tissues might be helpful for molecular biology research or the development of new target drugs for treating cases that are refractory to chemotherapy. Chemotherapy, however, may reduce or alter the distribution of GC tissue on the surface, making the detection of GC tissue during upper endoscopy challenging. Probe-based confocal laser endomicroscopy (pCLE) is a new technology that enables histological diagnosis by magnifying the mucous membrane to a microscopic level. Here, we evaluated whether pCLE could increase the yield of endoscopic biopsy for GC compared to white-light endoscopy (WLE) with magnifying narrow-band imaging (M-NBI) in GC patients receiving chemotherapy with its powerful imaging technique. Patients underwent WLE/M-NBI and pCLE for the detection of residual GC for the purpose of response evaluation or clinical trial registration. After WLE/M-NBI and pCLE, each residual GC lesion was biopsied for histological analysis. A total of 23 patients were enrolled between January 2018 and June 2020. Overall, pCLE showed significantly higher sensitivity and negative predictive value than WLE/M-NBI. The accuracy of pCLE was superior to that of WLE/M-NBI. Moreover, pCLE showed better predictive ability for residual GC than WLE/M-NBI, while WLE/M-NBI and pCLE showed inconsistent results. pCLE diagnosed residual GC more accurately than WLE/M-NBI, which resulted in an increased number of GC tissues collected during the endoscopic biopsy.

11 April 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
YKYuna Kim
Yuna Kim
JKJae Hyun Kim
Jae Hyun Kim
EKEun-Ae Kang
Eun-Ae Kang
SPSoo Jung Park
Soo Jung Park
JPJae-Jun Park
Jae-Jun Park
Seong Ran JeonSeong Ran Jeon
Seong Ran Jeon
Introduction: The impact of device-assisted enteroscopy (DAE) on long-term rebleeding in patients with obscure gastrointestinal bleeding (OGIB) exhibiting detectable small-bowel lesions remains unclear. We investigated the long-term rebleeding rate and predictive factors for DAE in patients with OGIB. Method: Patients with OGIB with small bowel lesions detected through DAE were enrolled at three Korean tertiary hospitals. Predictive risk factors associated with rebleeding were analyzed using the Cox regression analysis. Results: From April 2008 to April 2021, 141 patients were enrolled, including 38 patients (27.0%) with rebleeding. The rebleeding rates at 1, 2, and 3 years were 25.0%, 29.6%, and 31.1%, respectively. The Cox regression analysis revealed that multiple small-bowel lesions (hazard ratio [HR]: 2.551, 95% confidence interval [CI]: 1.157–5.627, p = 0.020), the need for more than five packed red blood cells (RBC) transfusions (HR: 2.704, 95% CI: 1.412–5.181, p = 0.003), and ulcerative lesions (HR: 1.992, 95% CI: 1.037–3.826, p = 0.039) were positively associated with rebleeding. Therapeutic interventions for patients with detectable lesions, overt bleeding (vs. occult bleeding), comorbidities, and medications were not associated with rebleeding. Conclusion: More than 25% of patients with OGIB having detectable small-bowel lesions had rebleeding. Patients with multiple lesions, a requirement of more than five packed RBC transfusions, and ulcerative lesions were associated with a higher risk of rebleeding.